Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.
Individual Disclosures for the NCCN Chronic Myeloid Leukemia Panel
This article was updated from the print version: the link to prescribing information for TKI therapies (under “Management of Hematologic Toxicities of TKI Therapy”) was updated with a new url.
MeloJV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375–2384.883982810.1182/blood.V88.7.2375.bloodjournal8872375)| false
JamiesonCHM, AillesLE, DyllaSJ, et al.. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med2004;351:657–667.
JamiesonCHM, AillesLE, DyllaSJ, . Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657–667.1530666710.1056/NEJMoa040258)| false
Douet-GuilbertN, MorelF, Le CharpentierT, et al.. Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. Anticancer Res2004;24:2535–2539.
Douet-GuilbertN, MorelF, Le CharpentierT, . Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. Anticancer Res 2004;24:2535–2539.15330210)| false
SeongDC, KantarjianHM, RoJY, et al.. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood1995;86:2343–2349.
SeongDC, KantarjianHM, RoJY, . Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood 1995;86:2343–2349.766298010.1182/blood.V86.6.2343.bloodjournal8662343)| false
DewaldGW, WyattWA, JuneauAL, et al.. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood1998;91:3357–3365.
KantarjianHM, TalpazM, CortesJ, et al.. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res2003;9:160–166.
KantarjianHM, TalpazM, CortesJ, . Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003;9:160–166.12538464)| false
HughesT, DeiningerM, HochhausA, et al.. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood2006;108:28–37.
HughesT, DeiningerM, HochhausA, . Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.10.1182/blood-2006-01-009216522812)| false
BiernauxC, LoosM, SelsA, et al.. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood1995;86:3118–3122.
BiernauxC, LoosM, SelsA, . Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995;86:3118–3122.10.1182/blood.V86.8.3118.3118)| false
BoseS, DeiningerM, Gora-TyborJ, et al.. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood1998;92:3362–3367.
BoseS, DeiningerM, Gora-TyborJ, . The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998;92:3362–3367.10.1182/blood.V92.9.33629787174)| false
BaccaraniM, CastagnettiF, GugliottaG, et al.. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia2019;33:1173–1183.
BaccaraniM, CastagnettiF, GugliottaG, . The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 2019;33:1173–1183.3067500810.1038/s41375-018-0341-4)| false
HanfsteinB, LausekerM, HehlmannR, et al.. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica2014;99:1441–1447.
JainP, KantarjianH, PatelKP, et al.. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood2016;127:1269–1275.
JainP, KantarjianH, PatelKP, . Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 2016;127:1269–1275.2672989710.1182/blood-2015-10-674242)| false
CastagnettiF, GugliottaG, BrecciaM, et al.. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol2017;92:797–805.
CastagnettiF, GugliottaG, BrecciaM, . The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol 2017;92:797–805.10.1002/ajh.2477428466557)| false
ErcaliskanA, EskazanAE. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer2018;124:3806–3818.
ErcaliskanA, EskazanAE. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer 2018;124:3806–3818.10.1002/cncr.3140829694669)| false
PfirrmannM, EvtimovaD, SausseleS, et al.. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. J Cancer Res Clin Oncol2017;143:843–850.
PfirrmannM, EvtimovaD, SausseleS, . No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. J Cancer Res Clin Oncol 2017;143:843–850.2808371110.1007/s00432-016-2321-2)| false
VermaD, KantarjianHM, JonesD, et al.. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood2009;114:2232–2235.
ArunAK, SenthamizhselviA, ManiS, et al.. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. Int J Lab Hematol2017;39:235–242.
GongZ, MedeirosLJ, CortesJE, et al.. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J2017;7:e583.
QinYZ, JiangQ, JiangH, et al.. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. Br J Haematol2018;182:693–700.
QinYZ, JiangQ, JiangH, . Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. Br J Haematol 2018;182:693–700.10.1111/bjh.1545329974949)| false
XueM, WangQ, HuoL, et al.. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts. Leuk Lymphoma2019;60:3051–3057.
VerstovsekS, LinH, KantarjianH, et al.. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer2002;94:2416–2425.
VerstovsekS, LinH, KantarjianH, . Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer 2002;94:2416–2425.10.1002/cncr.1049012015767)| false
LangabeerSE, McCarronSL, KellyJ, et al.. Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring. Case Rep Hematol2012;2012:458716.
LangabeerSE, McCarronSL, KellyJ, . Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring. Case Rep Hematol 2012;2012:458716.22937329)| false
CrampeM, HaslamK, KellyJ, et al.. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring. Hematol Oncol Stem Cell Ther2017;10:85–88.
CrampeM, HaslamK, KellyJ, . Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring. Hematol Oncol Stem Cell Ther 2017;10:85–88.10.1016/j.hemonc.2016.02.002)| false
ShanmuganathanN, HughesTP. Molecular monitoring in CML: how deep? How often? How should it influence therapy?Hematology (Am Soc Hematol Educ Program)2018;2018:168–176.
ShanmuganathanN, HughesTP. Molecular monitoring in CML: how deep? How often? How should it influence therapy?Hematology (Am Soc Hematol Educ Program) 2018;2018:168–176.10.1182/asheducation-2018.1.16830504306)| false
BurmeisterT, ReinhardtR. A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. Leuk Res 2008;32:579–585.10.1016/j.leukres.2007.08.01717928051)| false
BennourA, OuahchiI, MoezM, et al.. Comprehensive analysis of BCR/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR. Clin Lab2012;58:433–439.
MirR, AhmadI, JavidJ, et al.. Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients. Indian J Cancer2015;52:314–318.
MirR, AhmadI, JavidJ, . Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients. Indian J Cancer 2015;52:314–318.10.4103/0019-509X.17674126905124)| false
PaganiIS, DangP, SaundersVA, et al.. Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia [published online June 6, 2020]. Leuk Lymphoma,doi: 10.1080/10428194.2020.1772476
PaganiIS, DangP, SaundersVA, . Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia [published online June 6, 2020]. Leuk Lymphoma,doi: 10.1080/10428194.2020.1772476)| false
CortesJE, TalpazM, GilesF, et al.. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood2003;101:3794–3800.
O’DwyerME, MauroMJ, BlasdelC, et al.. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood2004;103:451–455.
O’DwyerME, MauroMJ, BlasdelC, . Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004;103:451–455.1451231210.1182/blood-2003-02-0371)| false
WangW, CortesJE, LinP, et al.. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood2015;126:1699–1706.
WangW, CortesJE, LinP, . Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood 2015;126:1699–1706.10.1182/blood-2015-05-64648926243778)| false
WangW, TangG, CortesJE, et al.. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol2015;8:32.
WangW, CortesJE, TangG, et al.. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood2016;127:2742–2750.
WangW, CortesJE, TangG, . Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 2016;127:2742–2750.10.1182/blood-2016-01-69023027006386)| false
VermaD, KantarjianH, ShanJ, et al.. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer2010;116:2673–2681.
VermaD, KantarjianH, ShanJ, . Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010;116:2673–2681.20499401)| false
FabariusA, KalmantiL, DietzCT, et al.. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol2015;94:2015–2024.
FabariusA, KalmantiL, DietzCT, . Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol 2015;94:2015–2024.10.1007/s00277-015-2494-926385387)| false
FabariusA, LeitnerA, HochhausA, et al.. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood2011;118:6760–6768.
FabariusA, LeitnerA, HochhausA, . Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011;118:6760–6768.10.1182/blood-2011-08-37390222039253)| false
AlhuraijiA, KantarjianH, BodduP, et al.. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol2018;93:84–90.
AlhuraijiA, KantarjianH, BodduP, . Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 2018;93:84–90.2902726110.1002/ajh.24943)| false
BummT, MüllerC, Al-AliH-K, et al.. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood2003;101:1941–1949.
BummT, MüllerC, Al-AliH-K, . Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003;101:1941–1949.1241129810.1182/blood-2002-07-2053)| false
FeldmanE, NajfeldV, SchusterM, et al.. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol2003;31:702–707.
FeldmanE, NajfeldV, SchusterM, . The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol 2003;31:702–707.10.1016/S0301-472X(03)00176-012901975)| false
MedinaJ, KantarjianH, TalpazM, et al.. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer2003;98:1905–1911.
MedinaJ, KantarjianH, TalpazM, . Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905–1911.10.1002/cncr.1172914584073)| false
TerreC, EclacheV, RousselotP, et al.. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia2004;18:1340–1346.
DeiningerMW, CortesJ, PaquetteR, et al.. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer2007;110:1509–1519.
DeiningerMW, CortesJ, PaquetteR, . The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007;110:1509–1519.1770209310.1002/cncr.22936)| false
JabbourE, KantarjianHM, AbruzzoLV, et al.. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood2007;110:2991–2995.
JabbourE, KantarjianHM, AbruzzoLV, . Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007;110:2991–2995.10.1182/blood-2007-01-07004517625066)| false
VignettiM, FaziP, CiminoG, et al.. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood2007;109:3676–3678.
VignettiM, FaziP, CiminoG, . Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood 2007;109:3676–3678.17213285)| false
FabariusA, HaferlachC, MüllerMC, et al.. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica2007;92:834–837.
FabariusA, HaferlachC, MüllerMC, . Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007;92:834–837.10.3324/haematol.1106417550857)| false
BaldazziC, LuattiS, MarzocchiG, et al.. Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Leuk Res2009;33:e218–e220.
BaldazziC, LuattiS, MarzocchiG, . Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Leuk Res 2009;33:e218–e220.10.1016/j.leukres.2009.05.01019525008)| false
WangH, JinJ, WangY, et al.. Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy. Ann Hematol2013;92:1625–1632.
WangH, JinJ, WangY, . Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy. Ann Hematol 2013;92:1625–1632.10.1007/s00277-013-1816-z23793947)| false
NiH, SunX, XuY, et al.. Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors. Cancer Genet2019;238:44–49.
NiH, SunX, XuY, . Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors. Cancer Genet 2019;238:44–49.10.1016/j.cancergen.2019.07.00831425925)| false
ShengG, XueM, WangQ, et al.. Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments. Leuk Lymphoma2019;60:3503–3511.
IssaGC, KantarjianHM, GonzalezGN, et al.. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood2017;130:2084–2091.
KarimataK, MasukoM, UshikiT, et al.. Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia. Intern Med2011;50:481–485.
KarimataK, MasukoM, UshikiT, . Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia. Intern Med 2011;50:481–485.10.2169/internalmedicine.50.4481)| false
NavarroJT, FeliuE, GrauJ, et al.. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol2007;82:849–851.
NavarroJT, FeliuE, GrauJ, . Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol 2007;82:849–851.10.1002/ajh.2085917563075)| false
BidetA, DulucqS, SmolT, et al.. Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Haematologica2019;104:1150–1155.
BidetA, DulucqS, SmolT, . Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Haematologica 2019;104:1150–1155.10.3324/haematol.2018.20880130573507)| false
SoveriniS, De BenedittisC, CastagnettiF, et al.. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. BMC Cancer2016;16:572.
SoveriniS, De BenedittisC, CastagnettiF, . In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. BMC Cancer 2016;16:572.10.1186/s12885-016-2635-027485109)| false
KizilorsA, CrisàE, LeaN, et al.. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. Lancet Haematol2019;6:e276–e284.
SoveriniS, AbruzzeseE, BocchiaM, et al.. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. J Hematol Oncol2019;12:131.
SoveriniS, BavaroL, De BenedittisC, et al.. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood2020;135:534–541.
SoveriniS, BavaroL, De BenedittisC, . Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood 2020;135:534–541.3187721110.1182/blood.2019002969)| false
HasfordJ, PfirrmannM, HehlmannR, et al.. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst1998;90:850–858.
HasfordJ, PfirrmannM, HehlmannR, . A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998;90:850–858.10.1093/jnci/90.11.8509625174)| false
PfirrmannM, BaccaraniM, SausseleS, et al.. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia2016;30:48–56.
PfirrmannM, BaccaraniM, SausseleS, . Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016;30:48–56.2641646210.1038/leu.2015.261)| false
HochhausA, LarsonRA, GuilhotF, . Long-term outcomes of imatinib treatment of chronic myeloid leukemia. N Engl J Med 2017;376:917–927.2827302810.1056/NEJMoa1609324)| false
CortesJE, SaglioG, KantarjianHM, et al.. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol2016;34:2333–2340.
CortesJE, SaglioG, KantarjianHM, . Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol 2016;34:2333–2340.10.1200/JCO.2015.64.889927217448)| false
HochhausA, SaglioG, HughesTP, et al.. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia2016;30:1044–1054.
HochhausA, SaglioG, HughesTP, . Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016;30:1044–1054.10.1038/leu.2016.526837842)| false
CortesJE, Gambacorti-PasseriniC, DeiningerMW, et al.. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol2018;36:231–237.
BaccaraniM, DrukerBJ, BranfordS, et al.. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol2014;99:616–624.
BaccaraniM, DrukerBJ, BranfordS, . Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol 2014;99:616–624.10.1007/s12185-014-1566-224658916)| false
HehlmannR, LausekerM, SaußeleS, et al.. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia2017;31:2398–2406.
HehlmannR, LausekerM, SaußeleS, . Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 2017;31:2398–2406.10.1038/leu.2017.25328804124)| false
HoffmannVS, HasfordJ, DeiningerM, et al.. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. J Cancer Res Clin Oncol2017;143:1311–1318.
HoffmannVS, HasfordJ, DeiningerM, . Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. J Cancer Res Clin Oncol 2017;143:1311–1318.2827586610.1007/s00432-017-2385-7)| false
HughesTP, LaneuvilleP, RousselotP, et al.. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica2019;104:93–101.
HughesTP, LaneuvilleP, RousselotP, . Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica 2019;104:93–101.3009339810.3324/haematol.2018.188987)| false
PorkkaK, KhouryHJ, PaquetteRL, et al.. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer2010;116:377–386.
PorkkaK, KhouryHJ, PaquetteRL, . Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377–386.1992478710.1002/cncr.24734)| false
CirmiS, El AbdA, LetinierL, et al.. Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS). Cancers (Basel)2020;12:826.
CirmiS, El AbdA, LetinierL, . Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS). Cancers (Basel) 2020;12:826.10.3390/cancers12040826)| false
BergeronA, RéaD, LevyV, et al.. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med2007;176:814–818.
BergeronA, RéaD, LevyV, . Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814–818.1760027710.1164/rccm.200705-715CR)| false
SerpaM, SanabaniSS, BenditI, et al.. Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. Clin Med Insights Oncol2010;4:155–162.
SerpaM, SanabaniSS, BenditI, . Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. Clin Med Insights Oncol 2010;4:155–162.2123429610.4137/CMO.S6413)| false
EfficaceF, BaccaraniM, BrecciaM, et al.. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia2013;27:1511–1519.
EfficaceF, BaccaraniM, BrecciaM, . Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013;27:1511–1519.10.1038/leu.2013.5123417029)| false
BermanE, NicolaidesM, MakiRG, . Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006–2013.10.1056/NEJMoa05114016687713)| false
BermanE, GirotraM, ChengC, et al.. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res2013;37:790–794.
BermanE, GirotraM, ChengC, . Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res 2013;37:790–794.10.1016/j.leukres.2013.02.005)| false
AleemA. Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther 2009;2:358–361.10.1016/S1658-3876(09)50026-X20118061)| false
SakuraiM, KikuchiT, KariganeD, et al.. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. Int J Hematol2019;109:292–298.
SakuraiM, KikuchiT, KariganeD, . Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. Int J Hematol 2019;109:292–298.3068066810.1007/s12185-019-02596-z)| false
AichbergerKJ, HerndlhoferS, SchernthanerG-H, et al.. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol2011;86:533–539.
AichbergerKJ, HerndlhoferS, SchernthanerG-H, . Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 2011;86:533–539.10.1002/ajh.2203721538470)| false
TefferiA, LetendreL. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol2011;86:610–611.
TefferiA, LetendreL. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol 2011;86:610–611.10.1002/ajh.2205121630307)| false
GilesFJ, MauroMJ, HongF, et al.. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia2013;27:1310–1315.
GilesFJ, MauroMJ, HongF, . Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013;27:1310–1315.10.1038/leu.2013.6923459450)| false
AssunçãoPM, LanaTP, DelamainMT, et al.. Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk2019;19:162–166.
CaocciG, MulasO, BonifacioM, et al.. Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. Int J Cardiol2019;288:124–127.
CaocciG, MulasO, BonifacioM, . Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. Int J Cardiol 2019;288:124–127.3102949810.1016/j.ijcard.2019.04.051)| false
TokuhiraM, KimuraY, SugimotoK, et al.. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol2018;35:38.
TokuhiraM, KimuraY, SugimotoK, . Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol 2018;35:38.2944217910.1007/s12032-018-1093-8)| false
Quintas-CardamaA, KantarjianH, O’BrienS, et al.. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer2004;100:2592–2597.
Quintás-CardamaA, De Souza SantosFP, KantarjianH, et al.. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer2009;115:3935–3943.
Quintás-CardamaA, De Souza SantosFP, KantarjianH, . Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 2009;115:3935–3943.10.1002/cncr.2443219517473)| false
SantosFP, AlvaradoY, KantarjianH, et al.. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer2011;117:982–991.
SantosFP, AlvaradoY, KantarjianH, . Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 2011;117:982–991.2096050210.1002/cncr.25533)| false
ReinholdU, HennigE, LeibleinS, et al.. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia2003;17:1925–1929.
ReinholdU, HennigE, LeibleinS, . FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia 2003;17:1925–1929.1451303910.1038/sj.leu.2403077)| false
FugazzaG, MiglinoM, BruzzoneR, et al.. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate. J Exp Clin Cancer Res2004;23:295–299.
FugazzaG, MiglinoM, BruzzoneR, . Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate. J Exp Clin Cancer Res 2004;23:295–299.15354415)| false
LandstromAP, KetterlingRP, KnudsonRA, et al.. Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma2006;47:2055–2061.
TestoniN, MarzocchiG, LuattiS, et al.. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood2009;114:4939–4943.
TestoniN, MarzocchiG, LuattiS, . Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009;114:4939–4943.1979751810.1182/blood-2009-07-229864)| false
LimaL, Bernal-MizrachiL, SaxeD, et al.. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer2011;117:1245–1252.
LimaL, Bernal-MizrachiL, SaxeD, . Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 2011;117:1245–1252.10.1002/cncr.2567821381013)| false
HughesTP, HochhausA, BranfordS, et al.. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood2010;116:3758–3765.
HughesTP, HochhausA, BranfordS, . Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758–3765.2067952810.1182/blood-2010-03-273979)| false
AkardLP, CortesJE, AlbitarM, et al.. Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study. Arch Pathol Lab Med2014;138:1186–1192.
AkardLP, CortesJE, AlbitarM, . Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study. Arch Pathol Lab Med 2014;138:1186–1192.10.5858/arpa.2013-0584-OA24308645)| false
BranfordS, CrossNCP, HochhausA, et al.. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia2006;20:1925–1930.
BranfordS, CrossNCP, HochhausA, . Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925–1930.10.1038/sj.leu.240438816990771)| false
CrossNC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22:355–365.1995908610.1016/j.beha.2009.04.001)| false
BranfordS, FletcherL, CrossNC, et al.. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood2008;112:3330–3338.
BranfordS, FletcherL, CrossNC, . Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330–3338.10.1182/blood-2008-04-150680)| false
GuérinA, ChenL, DeaK, et al.. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin2014;30:1345–1352.
GuérinA, ChenL, DeaK, . Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin 2014;30:1345–1352.10.1185/03007995.2014.90428124640967)| false
HanfsteinB, MüllerMC, HehlmannR, et al.. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia2012;26:2096–2102.
HanfsteinB, MüllerMC, HehlmannR, . Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012;26:2096–2102.2244650210.1038/leu.2012.85)| false
MarinD, IbrahimAR, LucasC, et al.. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol2012;30:232–238.
MarinD, IbrahimAR, LucasC, . Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232–238.2206739310.1200/JCO.2011.38.6565)| false
NeelakantanP, GerrardG, LucasC, et al.. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood2013;121:2739–2742.
NeelakantanP, GerrardG, LucasC, . Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013;121:2739–2742.2338074310.1182/blood-2012-11-466037)| false
NazhaA, KantarjianH, JainP, et al.. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica2013;98:1686–1688.
NazhaA, KantarjianH, JainP, . Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 2013;98:1686–1688.10.3324/haematol.2013.09028223812943)| false
BranfordS, YeungDT, ParkerWT, et al.. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood2014;124:511–518.
BranfordS, YeungDT, ParkerWT, . Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014;124:511–518.10.1182/blood-2014-03-56632324859364)| false
HanfsteinB, ShlyakhtoV, LausekerM, et al.. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia2014;28:1988–1992.
HanfsteinB, ShlyakhtoV, LausekerM, . Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014;28:1988–1992.10.1038/leu.2014.15324798484)| false
IriyamaN, FujisawaS, YoshidaC, et al.. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group. Am J Hematol2015;90:282–287.
IriyamaN, FujisawaS, YoshidaC, . Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group. Am J Hematol 2015;90:282–287.10.1002/ajh.23923)| false
HochhausA, O’BrienSG, GuilhotF, et al.. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia2009;23:1054–1061.
JabbourE, KantarjianH, O’BrienS, et al.. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood2011;118:4541–4546., quiz 4759.
JabbourE, KantarjianH, O’BrienS, . The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 2011;118:4541–4546., quiz 4759.2180385410.1182/blood-2011-04-348110)| false
DrukerBJ, GuilhotF, O’BrienSG, et al.. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med2006;355:2408–2417.
DrukerBJ, GuilhotF, O’BrienSG, . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.10.1056/NEJMoa06286717151364)| false
PressRD, GalderisiC, YangR, et al.. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res2007;13:6136–6143.
PressRD, GalderisiC, YangR, . A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007;13:6136–6143.10.1158/1078-0432.CCR-07-111217947479)| false
de LavalladeH, ApperleyJF, KhorashadJS, et al.. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol2008;26:3358–3363.
de LavalladeH, ApperleyJF, KhorashadJS, . Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3363.10.1200/JCO.2007.15.8154)| false
MarinD, MilojkovicD, OlavarriaE, et al.. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood2008;112:4437–4444.
MarinD, MilojkovicD, OlavarriaE, . European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112:4437–4444.10.1182/blood-2008-06-16238818716134)| false
JabbourE, KantarjianHM, O’BrienS, et al.. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?J Clin Oncol2011;29:4260–4265.
JabbourE, KantarjianHM, O’BrienS, . Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?J Clin Oncol 2011;29:4260–4265.10.1200/JCO.2011.36.069321990394)| false
HehlmannR, MüllerMC, LausekerM, et al.. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol2014;32:415–423.
HehlmannR, MüllerMC, LausekerM, . Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014;32:415–423.10.1200/JCO.2013.49.902024297946)| false
SausseleS, HehlmannR, FabariusA, et al.. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia2018;32:1222–1228.
SausseleS, HehlmannR, FabariusA, . Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. Leukemia 2018;32:1222–1228.2947907010.1038/s41375-018-0055-7)| false
CervantesF, López-GarridoP, MonteroMI, et al.. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica2010;95:1317–1324.
CervantesF, López-GarridoP, MonteroMI, . Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 2010;95:1317–1324.10.3324/haematol.2009.02115420220063)| false
KantarjianH, CortesJ. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol2011;29:1512–1516.
KantarjianH, CortesJ. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:1512–1516.10.1200/JCO.2010.33.917621422414)| false
ShahNP, RousselotP, SchifferC, et al.. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol2016;91:869–874.
ShahNP, RousselotP, SchifferC, . Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 2016;91:869–874.10.1002/ajh.2442327192969)| false
GilesFJ, le CoutrePD, Pinilla-IbarzJ, et al.. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia2013;27:107–112.
GilesFJ, le CoutrePD, Pinilla-IbarzJ, . Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107–112.10.1038/leu.2012.18122763385)| false
Gambacorti-PasseriniC, CortesJE, LiptonJH, et al.. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica2018;103:1298–1307.
Gambacorti-PasseriniC, CortesJE, LiptonJH, . Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 2018;103:1298–1307.10.3324/haematol.2017.171249)| false
CortesJE, KimD-W, Pinilla-IbarzJ, et al.. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood2018;132:393–404.
CortesJE, KimD-W, Pinilla-IbarzJ, . Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018;132:393–404.10.1182/blood-2016-09-73908629567798)| false
KantarjianHM, TalpazM, O’BrienS, et al.. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood2003;101:473–475.
KantarjianHM, TalpazM, O’BrienS, . Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473–475.1239338510.1182/blood-2002-05-1451)| false
MarinD, GoldmanJM, OlavarriaE, et al.. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood2003;102:2702–2703., author reply 2703–2704.
MarinD, GoldmanJM, OlavarriaE, . Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003;102:2702–2703., author reply 2703–2704.10.1182/blood-2003-06-204214504074)| false
JabbourE, KantarjianHM, JonesD, et al.. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood2009;113:2154–2160.
JabbourE, KantarjianHM, JonesD, . Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154–2160.10.1182/blood-2008-04-15434419060245)| false
KantarjianHM, LarsonRA, GuilhotF, et al.. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer2009;115:551–560.
KantarjianHM, LarsonRA, GuilhotF, . Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551–560.1911734510.1002/cncr.24066)| false
YeungDT, OsbornMP, WhiteDL, et al.. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood2015;125:915–923.
YeungDT, OsbornMP, WhiteDL, . TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 2015;125:915–923.10.1182/blood-2014-07-59031525519749)| false
CortesJE, De SouzaCA, AyalaM, et al.. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol2016;3:e581–e591.
CortesJE, De SouzaCA, AyalaM, . Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol 2016;3:e581–e591.2789007310.1016/S2352-3026(16)30167-3)| false
CortesJE, KhouryHJ, KantarjianHM, et al.. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol2016;91:1206–1214.
CortesJE, KhouryHJ, KantarjianHM, . Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol 2016;91:1206–1214.10.1002/ajh.2453627531525)| false
García-GutiérrezV, MilojkovicD, Hernandez-BoludaJC, et al.. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. Ann Hematol2019;98:321–330.
García-GutiérrezV, MilojkovicD, Hernandez-BoludaJC, . Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. Ann Hematol 2019;98:321–330.10.1007/s00277-018-3507-230446802)| false
JainP, KantarjianH, BodduPC, et al.. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv2019;3:851–861.
CaocciG, MulasO, AbruzzeseE, et al.. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol2019;37:296–302.
CaocciG, MulasO, AbruzzeseE, . Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol 2019;37:296–302.10.1002/hon.260630892724)| false
CasavecchiaG, GalderisiM, NovoG, et al.. Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib. Heart Fail Rev2020;25:447–456.
CasavecchiaG, GalderisiM, NovoG, . Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib. Heart Fail Rev 2020;25:447–456.10.1007/s10741-020-09926-y32026180)| false
CortesJE, KantarjianH, ShahNP, . Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012;367:2075–2088.2319022110.1056/NEJMoa1205127)| false
DorerDJ, KnickerbockerRK, BaccaraniM, et al.. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res2016;48:84–91.
DorerDJ, KnickerbockerRK, BaccaraniM, . Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res 2016;48:84–91.2750563710.1016/j.leukres.2016.07.007)| false
IurloA, CattaneoD, OrofinoN, et al.. Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option. Clin Drug Investig2018;38:475–476.
GargRJ, KantarjianH, O’BrienS, et al.. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood2009;114:4361–4368.
GargRJ, KantarjianH, O’BrienS, . The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009;114:4361–4368.1972951710.1182/blood-2009-05-221531)| false
CortesJ, LiptonJH, ReaD, et al.. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood2012;120:2573–2580.
CortesJ, LiptonJH, ReaD, . Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012;120:2573–2580.10.1182/blood-2012-03-41530722896000)| false
CortesJ, DigumartiR, ParikhPM, et al.. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol2013;88:350–354.
CortesJ, DigumartiR, ParikhPM, . Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol 2013;88:350–354.10.1002/ajh.2340823468307)| false
van LeeuwenRW, van GelderT, MathijssenRH, et al.. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol2014;15:e315–e326.
van LeeuwenRW, van GelderT, MathijssenRH, . Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014;15:e315–e326.10.1016/S1470-2045(13)70579-5)| false
OsorioS, Escudero-VilaplanaV, Gómez-CenturiónI, et al.. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?Ann Hematol2018;97:2089–2098.
OsorioS, Escudero-VilaplanaV, Gómez-CenturiónI, . Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?Ann Hematol 2018;97:2089–2098.2995594310.1007/s00277-018-3413-7)| false
NoensL, van LierdeM-A, De BockR, et al.. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood2009;113:5401–5411.
NoensL, van LierdeM-A, De BockR, . Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401–5411.10.1182/blood-2008-12-19654319349618)| false
MarinD, BazeosA, MahonF-X, et al.. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol2010;28:2381–2388.
MarinD, BazeosA, MahonF-X, . Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381–2388.2038598610.1200/JCO.2009.26.3087)| false
IbrahimAR, EliassonL, ApperleyJF, et al.. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood2011;117:3733–3736.
IbrahimAR, EliassonL, ApperleyJF, . Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011;117:3733–3736.10.1182/blood-2010-10-30980721346253)| false
WuEQ, GuerinA, YuAP, et al.. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin2010;26:2861–2869.
WuEQ, GuerinA, YuAP, . Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26:2861–2869.2106213610.1185/03007995.2010.533648)| false
YoodMU, OliveriaSA, CzirakyM, et al.. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin2012;28:213–219.
YoodMU, OliveriaSA, CzirakyM, . Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 2012;28:213–219.2216821710.1185/03007995.2011.649849)| false
CornelisonM, JabbourEJ, WelchMA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol2012;10:14–24.
CornelisonM, JabbourEJ, WelchMA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner. J Support Oncol 2012;10:14–24.10.1016/j.suponc.2011.08.00122244674)| false
CortesJE, LiptonJH, MillerCB, et al.. Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH Study. Clin Lymphoma Myeloma Leuk2016;16:286–296.
CortesJE, LiptonJH, MillerCB, . Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH Study. Clin Lymphoma Myeloma Leuk 2016;16:286–296.2699375810.1016/j.clml.2016.02.002)| false
KimDW, SausseleS, WilliamsLA, et al.. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol2018;97:1357–1367.
KimDW, SausseleS, WilliamsLA, . Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol 2018;97:1357–1367.10.1007/s00277-018-3295-829556695)| false
HiwaseD, TanP, D’RozarioJ, et al.. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the phase IIIb ENESTswift study. Leuk Res2018;67:109–115.
HiwaseD, TanP, D’RozarioJ, . Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the phase IIIb ENESTswift study. Leuk Res 2018;67:109–115.10.1016/j.leukres.2018.02.01329494928)| false
ThomasJ, WangL, ClarkRE, . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–3745.1531597110.1182/blood-2003-12-4276)| false
MahonFX, HayetteS, LagardeV, et al.. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res2008;68:9809–9816.
MahonFX, HayetteS, LagardeV, . Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 2008;68:9809–9816.1904716010.1158/0008-5472.CAN-08-1008)| false
HegedusC, Ozvegy-LaczkaC, ApátiA, et al.. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol2009;158:1153–1164.
HegedusC, Ozvegy-LaczkaC, ApátiA, . Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009;158:1153–1164.10.1111/j.1476-5381.2009.00383.x19785662)| false
PicardS, TitierK, EtienneG, et al.. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood2007;109:3496–3499.
PicardS, TitierK, EtienneG, . Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496–3499.10.1182/blood-2006-07-03601217192396)| false
LarsonRA, DrukerBJ, GuilhotF, et al.. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood2008;111:4022–4028.
LarsonRA, DrukerBJ, GuilhotF, . Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022–4028.10.1182/blood-2007-10-11647518256322)| false
BouchetS, TitierK, MooreN, et al.. Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol2013;27:690–697.
BouchetS, TitierK, MooreN, . Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundam Clin Pharmacol 2013;27:690–697.10.1111/fcp.12007)| false
WhiteDL, RadichJ, SoveriniS, et al.. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica2012;97:907–914.
WhiteDL, RadichJ, SoveriniS, . Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica 2012;97:907–914.2220769010.3324/haematol.2011.056457)| false
GiannoudisA, DaviesA, LucasCM, et al.. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood2008;112:3348–3354.
GiannoudisA, DaviesA, LucasCM, . Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112:3348–3354.10.1182/blood-2007-10-11623618669873)| false
HiwaseDK, SaundersV, HewettD, et al.. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res2008;14:3881–3888.
DaviesA, JordanidesNE, GiannoudisA, et al.. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia2009;23:1999–2006.
DaviesA, JordanidesNE, GiannoudisA, . Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009;23:1999–2006.1971070210.1038/leu.2009.166)| false
WhiteDL, SaundersVA, DangP, et al.. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood2006;108:697–704.
WhiteDL, SaundersVA, DangP, . OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697–704.10.1182/blood-2005-11-468716597591)| false
BranfordS, RudzkiZ, WalshS, et al.. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood2003;102:276–283.
BranfordS, RudzkiZ, WalshS, . Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276–283.10.1182/blood-2002-09-289612623848)| false
SoveriniS, MartinelliG, RostiG, et al.. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol2005;23:4100–4109.
SoveriniS, MartinelliG, RostiG, . ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100–4109.15867198)| false
NicoliniFE, CormS, LêQH, et al.. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia2006;20:1061–1066.
NicoliniFE, CormS, LêQH, . Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006;20:1061–1066.10.1038/sj.leu.240423616642048)| false
SoveriniS, ColarossiS, GnaniA, et al.. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res2006;12:7374–7379.
SoveriniS, ColarossiS, GnaniA, . Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374–7379.1718941010.1158/1078-0432.CCR-06-1516)| false
KhorashadJS, de LavalladeH, ApperleyJF, et al.. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol2008;26:4806–4813.
KhorashadJS, de LavalladeH, ApperleyJF, . Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806–4813.10.1200/JCO.2008.16.995318645191)| false
SoveriniS, GnaniA, ColarossiS, et al.. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood2009;114:2168–2171.
SoveriniS, GnaniA, ColarossiS, . Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009;114:2168–2171.10.1182/blood-2009-01-19718619589924)| false
JabbourE, KantarjianH, JonesD, et al.. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood2008;112:53–55.
JabbourE, KantarjianH, JonesD, . Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008;112:53–55.10.1182/blood-2007-11-12395018403620)| false
SoveriniS, ColarossiS, GnaniA, et al.. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica2007;92:401–404.
SoveriniS, ColarossiS, GnaniA, . Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007;92:401–404.10.3324/haematol.1082217339191)| false
JabbourE, KantarjianHM, JonesD, et al.. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood2008;112:4839–4842.
MüllerMC, CortesJE, KimD-W, et al.. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood2009;114:4944–4953.
HughesT, SaglioG, BranfordS, et al.. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol2009;27:4204–4210.
HughesT, SaglioG, BranfordS, . Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009;27:4204–4210.1965205610.1200/JCO.2009.21.8230)| false
NaqviK, CortesJE, LuthraR, et al.. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol2018;107:689–695.
KhouryHJ, CortesJE, KantarjianHM, et al.. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood2012;119:3403–3412.
KhouryHJ, CortesJE, KantarjianHM, . Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403–3412.10.1182/blood-2011-11-39012022371878)| false
KhorashadJS, KelleyTW, SzankasiP, et al.. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood2013;121:489–498.
DeiningerMW, HodgsonJG, ShahNP, et al.. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood2016;127:703–712.
DeiningerMW, HodgsonJG, ShahNP, . Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood 2016;127:703–712.2660383910.1182/blood-2015-08-660977)| false
GrossmannV, KohlmannA, ZengerM, et al.. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia2011;25:557–560.
GrossmannV, KohlmannA, ZengerM, . A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 2011;25:557–560.10.1038/leu.2010.29821274004)| false
SchmidtM, RinkeJ, SchäferV, et al.. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia2014;28:2292–2299.
SoveriniS, de BenedittisC, ManciniM, et al.. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk2015;15(Suppl):S120–S128.
SoveriniS, de BenedittisC, ManciniM, . Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 2015;15(Suppl):S120–S128.2629726410.1016/j.clml.2015.02.035)| false
KimT, TyndelMS, KimHJ, et al.. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood2017;129:38–47.
TogasakiE, TakedaJ, YoshidaK, et al.. Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia. Blood Cancer J2017;7:e559.
BranfordS, WangP, YeungDT, et al.. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood2018;132:948–961.
BranfordS, KimDDH, ApperleyJF, et al.. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia2019;33:1835–1850.
BranfordS, KimDDH, ApperleyJF, . Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia 2019;33:1835–1850.3120928010.1038/s41375-019-0512-y)| false
Adnan AwadS, KankainenM, OjalaT, et al.. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Adv2020;4:546–559.
BranfordS, RudzkiZ, ParkinsonI, et al.. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood2004;104:2926–2932.
BranfordS, RudzkiZ, ParkinsonI, . Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004;104:2926–2932.10.1182/blood-2004-03-113415256429)| false
WangL, KnightK, LucasC, et al.. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica2006;91:235–239.
WangL, KnightK, LucasC, . The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006;91:235–239.16461309)| false
KantarjianHM, ShanJ, JonesD, et al.. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol2009;27:3659–3663.
KantarjianHM, ShanJ, JonesD, . Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009;27:3659–3663.1948738310.1200/JCO.2008.18.6999)| false
MarinD, KhorashadJS, ForoniL, et al.. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?Br J Haematol2009;145:373–375.
MarinD, KhorashadJS, ForoniL, . Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?Br J Haematol 2009;145:373–375.1934439710.1111/j.1365-2141.2009.07646.x)| false
PressRD, WillisSG, LaudadioJ, et al.. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood2009;114:2598–2605.
PressRD, WillisSG, LaudadioJ, . Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009;114:2598–2605.1962570710.1182/blood-2008-08-173674)| false
MahonFX, RéaD, GuilhotJ, et al.. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol2010;11:1029–1035.
